{
    "clinical_study": {
        "@rank": "26888", 
        "arm_group": {
            "arm_group_label": "POL7080", 
            "arm_group_type": "Experimental", 
            "description": "POL7080 administered daily"
        }, 
        "brief_summary": {
            "textblock": "To test whether POL7080 is effective in patients with exacerbation of non-cystic fibrosis\n      bronchiectasis caused by Pseudomonas aeruginosa infection."
        }, 
        "brief_title": "Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bronchiectasis", 
            "Lower Respiratory Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bronchiectasis", 
                "Fibrosis", 
                "Respiratory Tract Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Patients will be recruited after written informed consent.\n\n        -  Adverse events will be coded using Medical Dictionary for regulatory activities\n           (MedDRA).\n\n        -  Descriptive statistics will be used for all the safety and efficacy variables."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female aged \u226518 to <80 years and suffering from exacerbation of non-cystic\n             fibrosis bronchiectasis due to Pseudomonas aeruginosa infection\n\n          2. Sputum sample collected for culture before starting treatment\n\n        Exclusion Criteria:\n\n          1. Female patients who are pregnant or breast feeding or unwilling to follow reliable\n             method of contraception\n\n          2. Subjects suffering from cystic fibrosis, active pulmonary mycobacterial infection,\n             end stage chronic obstructive pulmonary disease on long term oxygen therapy, severe\n             uncontrolled asthma, active sarcoidosis and active allergic broncho-pulmonary\n             aspergillosis\n\n          3. Current exacerbation of bronchiectasis is associated with lung abscess or empyema\n\n          4. Current exacerbation episode is suspected or documented to be due to pathogens other\n             than Pseudomonas aeruginosa\n\n          5. Patients with known HIV infection with CD4+ (cluster of differentiation 4) cell count\n             < 200/mm3\n\n          6. Patients who are currently enrolled in, or have not yet completed at least 30 days\n             since ending another investigational device or drug trial or are receiving other\n             investigational agent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096315", 
            "org_study_id": "POL7080-002"
        }, 
        "intervention": {
            "arm_group_label": "POL7080", 
            "description": "Intravenous infusion", 
            "intervention_name": "POL7080", 
            "intervention_type": "Drug", 
            "other_name": "POL7080"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "POL7080", 
            "Pseudomonas aeruginosa", 
            "Non cystic fibrosis bronchiectasis", 
            "Exacerbation"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Bellvitge"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital La Fe"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "City of Edinburgh", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Royal Infirmary"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II, Open-label, Multicenter Study to Assess the Tolerance, Safety, Efficacy and Pharmacokinetics/Pharmacodynamics (PK/PD) of POL7080 in the Treatment of Patients With Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis Due to Pseudomonas Aeruginosa Infection Requiring Intravenous Treatment", 
        "other_outcome": {
            "description": "Blood samples to measure POL7080 concentrations before, during and after administration of POL7080", 
            "measure": "To measure the plasma concentrations of POL7080", 
            "safety_issue": "No", 
            "time_frame": "Day 3"
        }, 
        "overall_contact": {
            "email": "Klaus.Dembowsky@polyphor.com", 
            "last_name": "Klaus Dembowsky, MD", 
            "phone": "+41 61 567 16 00"
        }, 
        "overall_contact_backup": {
            "email": "Manickam.Rangaraju@polyphor.com", 
            "last_name": "Manickam Rangaraju, MD", 
            "phone": "+41 61 567 16 00"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital Clinic, Barcelona, SPAIN", 
                "last_name": "Eva Polverino, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Royal Infirmary, Edinburgh, U.K.", 
                "last_name": "Adam Hill, MD PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reduction in CFU/mL (colony forming units/mL)  of Pseudomonas aeruginosa", 
            "measure": "Sputum bacterial clearance", 
            "safety_issue": "No", 
            "time_frame": "Day 4, Day 5, Day 10, Day 15 and Day 20"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096315"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of adverse events reported by the patients or observed by the investigator will be recorded. Onset, end date, severity, causal relationship, outcome and measures taken will be summarized. Death, discontinuations and serious adverse events will be listed and narrative summaries will be provided.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Daily assessment up to 20 days from informed consent."
            }, 
            {
                "description": "The number and severity of abnormal blood chemistry and hematology findings will be summarized descriptively and compared to baseline. Clinically significant values/outliers will be listed and commented.", 
                "measure": "Laboratory abnormalities.", 
                "safety_issue": "Yes", 
                "time_frame": "Day 4, Day 10, Day 15 and Day 20"
            }, 
            {
                "description": "Reduction in 24 hours sputum volume as compared to baseline will be computed", 
                "measure": "Volume of sputum in 24 hours", 
                "safety_issue": "No", 
                "time_frame": "Day 4, Day 10, Day 15 and Day 20"
            }
        ], 
        "source": "Polyphor Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Polyphor Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}